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Abstract: Antibiotic-tolerant persister bacteria involve frequent treatment failures, relapsing infections
and the need for extended antibiotic treatment. The virulence of an intracellular human pathogen
C. pneumoniae is tightly linked to its propensity for persistence and means for its chemosensitization are
urgently needed. In the current work, persistence of C. pneumoniae clinical isolate CV6 was studied in
THP-1 macrophages using quantitative PCR and quantitative culture. A dibenzocyclooctadiene lignan
schisandrin reverted C. pneumoniae persistence and promoted productive infection. The concomitant
administration of schisandrin and azithromycin resulted in significantly improved bacterial eradication
compared to sole azithromycin treatment. In addition, the closely related lignan schisandrin C
was superior to azithromycin in eradicating the C. pneumoniae infection from the macrophages.
The observed chemosensitization of C. pneumoniae was associated with the suppression of cellular
glutathione pools by the lignans, implying to a previously unknown aspect of chlamydia–host
interactions. These data indicate that schisandrin lignans induce a phenotypic switch in C. pneumoniae,
promoting the productive and antibiotic-susceptible phenotype instead of persistence. By this means,
these medicinal plant -derived compounds show potential as adjuvant therapies for intracellular
bacteria resuscitation.
Keywords: bacterial persistence; dormancy; glutathione; antibacterial agent; adjuvant therapy;
natural product
1. Introduction
In the course of evolution, bacteria have developed various means for protecting themselves
from unfavorable conditions. Described as a reversible dormant phenotype, persistence has been
acknowledged as one major survival strategy of bacteria [1–3]. Bacterial persistence is considered a
major cause of antibiotic treatment failures and relapsing infections and it also contributes to the rise
of antibiotic resistance [4]. Owing to redundant mechanisms, these phenotypical variants are able
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to survive under antibiotic pressure and revert back to metabolically more active phenotype when
stressful conditions are cleared off.
In clinical settings, bacterial dormancy is associated with hard-to-treat infections via two
mechanistically overlapping phenomena; persistent infections evading host immune responses
and antibiotic persistence defined based on the presence of drug-tolerant subpopulations of bacteria.
Both of these features are typical to infections caused by Chlamydia pneumoniae, a gram-negative
obligate intracellular human pathogen that causes respiratory infections from dry cough to pneumonia.
While a majority of C. pneumoniae infections are subclinical, with nearly everyone getting infected
during their lifetime, the bacterium is also responsible for 5%–10% of community-acquired pneumonia
cases worldwide [5,6]. C. pneumoniae has a unique biphasic development cycle, where the bacteria
switch between an infectious form elementary body (EB) and a non-infectious metabolically active
reticulate body (RB) [7]. The acute phase may also be followed by a persistent infection [8], occurring
spontaneously in monocytes and macrophages [6,9]. A morphological hallmark of the persistent
phenotype is the emergence of abnormal RBs with low metabolic activity and replication [8,10].
This viable but non-cultivable phenotype of C. pneumoniae is also characterized by the impairment of
transcription and translation as well as the cessation of infectious EB progeny production [11].
Besides the acute respiratory illnesses, C. pneumoniae has been related to many chronic inflammatory
diseases, such as atherosclerosis and asthma exacerbation [12,13]. The ability of C. pneumoniae to
persist in infected cell populations forms the basis for the hypotheses on these disease connections,
and monocytes and macrophages have a main role in the initiation of the chlamydial persistence [6,8].
Owing to its propensity for persistence, C. pneumoniae is a challenging target for antibacterial
therapy. The bacterium can be eradicated from permissive cell lines such as the airway epithelium
by macrolide and tetracycline antibiotics [14] but its complete eradication remains challenging.
New strategies for combatting the persistent chlamydial populations are thus needed. Within our
earlier work, we have identified the antichlamydial activity of dibenzocyclooctadiene lignans isolated
from a medicinal plant Schisandra chinensis on C. pneumoniae replication in respiratory epithelial
cells [15,16]. Based on the selectivity studies on other gram-negative and gram-positive bacteria as
well as by the lack of published reports on antibacterial effects of these lignans, they seem to exert
a narrow spectrum of antibacterial activity limited to Chlamydia spp. bacteria and possibly some
other intracellular pathogens. Rather than as antimicrobial agents, the S. chinensis-derived lignans
have been widely studied on their histoprotective effects on liver, heart, kidney, and central nervous
tissues [17–20].
To date, a variety of anti-persister molecules have been described against both gram-positive and
gram-negative human pathogens, major strategies involving direct eradication of the metabolically
quiescent cells by e.g., membrane-active compounds, bacterial resuscitation by boosting energy
metabolism and application of combination therapies [4]. According to current consensus, taking
persister bacteria into account is a critical success factor in antibacterial therapy. Regarding C. pneumoniae,
only a few membrane-active agents capable of affecting EB infectivity independent of metabolic activity
have been described [21,22] and to date, no agents capable to eradicate the persistent intracellular forms
of the bacterium have been described. Furthermore, current standard methods for antichlamydial
susceptibility testing are based solely on permissive epithelial cells and involve the suppression of host
cell responses by cycloheximide treatment [23,24].
To identify antichlamydial agents yielding improved eradication of C. pneumoniae also in the
persistence prone, nonpermissive host cell populations, we studied C. pneumoniae infection in THP-1
macrophages by quantitative PCR and quantitative culture. With this model, we identified the
differential antichlamydial potency of schisandrin and schisandrin C on C. pneumoniae persistence.
These dibenzocyclooctadiene lignans show activities that are qualitatively and quantitatively different
from each other and the standard of care antibiotic azithromycin. While schisandrin promoted the
productive C. pneumoniae infection, schisandrin C yielded a highly effective eradication of the infection.
Furthermore, combining schisandrin to azithromycin treatment resulted in significantly improved
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antibacterial effect than sole azithromycin treatment, indicating the potential of this approach as an
adjuvant therapy for current antibiotics.
2. Results
2.1. Schisandrin Lignans as Modulators of C. pneumoniae Infection
Encouraged by our earlier findings on the antichlamydial activity of dibenzocyclooctadiene
lignans against the productive, actively replicating Chlamydia spp. bacteria [15,16], three of these
lignans, schisandrin, schisandrin B, and schisandrin C (Figure 1) were evaluated for their efficacy
against C. pneumoniae in macrophages.
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To define lignan concentrations tolerated by the macrophages, THP-1 cell viability upon lignan
exposure was determined with two assays, the resazurin reduction assay and the intracellular
ATP quantification (Table 1). Schisandrin and schisandrin C were well tolerated after 24–144 h
exposure, but schisandrin B concentrations above 10 µM decreased THP-1 macrophage viability.
Since the C. pneumoniae infection caused a small but significant (24 h, P = 0.002; 48 h, P = 0.04; 72 h,
P = 0.043) increase in ATP levels the quantification of intracellular ATP was also performed in the
presence of C. pneumoniae infection, yielding viability values essentially similar to those observed in
noninfected cells.
Table 1. Impact of dibenzocyclooctadiene lignans on THP-1 macrophage cell viability with (Cpn +)
and without (Cpn -) C. pneumoniae infection.
24 h 48 h 72 h 144 h
Compound (µM) Res ATP Res ATP Res ATP Res
Cpn
-
Cpn
-
Cpn
+
Cpn
-
Cpn
-
Cpn
+
Cpn
-
Cpn
-
Cpn
+
Cpn
-
sch 25 118 113 120 * 105 172 122 93 103 99 127
sch 50 106 107 117 119 151 96 92 92 87 120
sch B 10 - 101 111 - 156 89 - 103 88 130
sch B 25 80 97 105 70 113 74 80 * 85 73 52 *
sch B 50 67 ** 79 *** 87 50 ** 92 57 69 53 *** 44 *** 1 **
sch C 25 89 94 100 78 139 96 111 102 90 122
sch C 50 79 90 108 69 121 81 101 93 82 * 81
Data are presented as viability percentages normalized to the values of 0.25% DMSO control. Statistical significance
is presented as marks of p-values: <0.05: *; <0.01: **; <0.001: *** (n = 3). Abbreviations: Cpn = C. pneumoniae, sch =
schisandrin, Res = resazurin.
The impact of the schisandrin lignans on C. pneumoniae growth kinetics was determined in THP-1
macrophages by following the bacterial genome copy numbers with qPCR in various ti e points from
2 to 144 h post infection.
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Azithromycin, the standard of care antibiotic for chlamydial infections at its typically used
concentration 20 nM did not suppress the bacterial replication in the macrophages. In contrast,
the same azithromycin concentration yields 99% inhibition in permissive respiratory epithelial cells
(Appendix A Figure A1). At 100 nM azithromycin reduced the C. pneumoniae genome numbers by
68% of infection at 72 h post infection and by 93% at 144 h post infection (Figure 2). This indicates
that C. pneumoniae survival is significantly improved under antibiotic pressure in the macrophages
compared to the epithelial cells. The prolonged antibiotic tolerance is a typical hallmark for the
presence of persister subpopulations [1].
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Figure 2. Impact of dibenzocyclooctadiene lignans on . pneumoniae growth kinetics in THP-1
macrophages. C lls were infect d at MOI 1 IFU/cell and . oniae genome copy numbers were
determin d with qPCR on ompA gen . Fresh mediu ed at 72 h. D t are shown as total
genome u bers of C. pneumoniae per well ± SEM (n = 4). tatistical significance is presented as marks
of p-values: <0.05: *; <0.01: **. Abbreviations: OI = multiplicity of infection.
As shown in Figure 2, 10 µM schisandrin B and 25 µM schisandrin C were as effective as 100 nM
azithromycin in reducing C. pneumoniae genome numbers at 72 h and 144 h after infection. At 50 µM,
schisandrin C was superior to all other samples assayed for C. pneumoniae genome number reduction
and showed a statistically significant difference to azithromycin in this respect. It yielded 95% reduction
in bacterial genome numbers at 72 h and 99% reduction at 144 h, respectively.
The effect of the schisandrin lignans on C. pneumoniae infectious progeny production in THP-1
macrophages was also evaluated. Within its productive life cycle, C. pneumoniae infectious progeny
production occurs typic lly 48–72 h post infection, involving ifferentiation of the newly formed
bacterial cells into EBs that leave the host cell to infect neighboring cells. For detecting the production
of infectious EB progenies in THP-1 macrophages, inoculation of infected THP-1 cell lysates and
culture medium supernatants into permissive human lung (HL) cells was carried out. By subsequent
immunostaining of chlamydial inclusions in the HL monolayers with chlamydia-specific anti-LPS
antibody, the quantities of infectious progeny in the original samples was determined.
As shown in Table 2, schisandrin B and schisandrin C decreased C. pneumoniae infectious progeny
production in a statistically significant manner at 72 and 144 h. In schisandrin C treated samples
(25 µM or 50 µM), not any characteristic inclusions were detected, and only some small irregular
inclusion-like structures were observed in HL monolayers inoculated with the cell lysates and none in
those inoculated with supernatant samples. In contrast, azithromycin failed to clear the cell lysates
from C. pneumoniae, yet azithromycin treated culture supernatants contained no bacterial progeny.
Interestingly, schisandrin increased the bacterial progeny levels in particular after 72 h post infection.
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At 25 µM schisandrin treatment resulted in a statistically significant increase in infectious EB quantities
detected in THP-1 cell lysates at 72 h post infection.
Table 2. The Impact of dibenzocyclooctadiene lignans on C. pneumoniae infectious progeny production.
Cell Lysate (IFU/mL Index) Supernatant (IFU/mL Index)
72 h 144 h 72 h 144 h
sch 25 µM 1.53 ± 0.06 * 3.11 ± 0.62 1.52 ± 0.33 2.82 ± 0.27
sch 50 µM 2.28 ± 0.38 1.03 ± 0.34 2.56 ± 0.64 0.93 ± 0.18
sch B 10 µM 0.10 ± 0.03 ** 0.01 ± 0.00 *** 0.28 ± 0.18 0.04 ± 0.01 ***
sch C 25 µM 0.00 ± 0.00 ** 0.00 ± 0.00 *** 0.00 ± 0.00 ** 0.00 ± 0.00 ***
sch C 50 µM 0.00 ± 0.00 ** 0.00 ± 0.00 *** 0.00 ± 0.00 ** 0.00 ± 0.00 ***
azithromycin 100 nM 0.18 ± 0.20 ** 0.05 ± 0.03 *** 0.30 ± 0.21 0.00 ± 0.00***
infection (IFU/mL) 49,700 ± 16,000 140,200 ± 22,800 5400 ± 2100 12,300 ± 700
MOI 1 infection was used in experiments. Data are normalized to the non-treated infection control and presented as
infectious units per mL (IFU/mL) ratios, showing as mean ± SEM. Results of non-treated samples are presented as
IFU/mL ± SEM. < 0.05: *; < 0.01: **; < 0.001: ***, (n = 4). Abbreviations: sch = schisandrin, IFU = inclusion forming
unit, MOI = multiplicity of infection.
2.2. Concomitant Administration of Schisandrin and Azithromycin
The impact of concomitant administration of schisandrin and azithromycin on C. pneumoniae
survival was determined. The ability of 25 µM schisandrin treatment to increase C. pneumoniae bacterial
progeny production indicates that this lignan concentration promotes C. pneumoniae productive
infection, shifting the balance of the intracellular bacteria populations to favor the replicative
state. The bacteriostatic activity of azithromycin is targeted to replicative bacteria, and it was thus
hypothesized that C. pneumoniae eradication in macrophages could be improved by the simultaneous
administration of the two compounds. Figure 3 presents data on experiments made to verify this.
Consistent with the findings shown above, schisandrin did not affect C. pneumoniae total genome copy
numbers and azithromycin yielded approximately 49% suppression on them at 72 h post infection
(Figure 3A). Treating the infection simultaneously with both compounds yielded approximately
91% reduction in C. pneumoniae genome copy numbers, which is statistically highly significant
(P value 0.00042) compared to sole azithromycin treatment. Furthermore, administering schisandrin
together with azithromycin drastically increased the eradication of progeny EBs from the cultures
(Figure 3B, P value 0.0022).
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Figure 3. Impact of the concomitant administration of schisandrin (25 µM) and azithromycin (100 nM)
on C. pneumoniae genome numbers (A) and EB progeny production (B). Data are normalized on the
non-treated infection control and shown as a mean ± SEM (n ≥ 4) statistical significance is presented as
marks of p-values: <0.01: **; <0.001: ***. Abbreviations: IFU = inclusion forming unit.
2.3. Role of Cellular Redox Status in the Effects of Schisandrin Lignans on C. pneumoniae Infection
As the dibenzocyclooctadiene lignans are known for their redox activities and changes in cellular
redox status have also been linked to bacterial persistence, we addressed the ifferential effects of
Molecules 2020, 25, 294 6 of 16
schisandrin and schisandrin C on C. pneumoniae infection by studying changes in cellular redox status.
As shown in Figure 4A, both multiplicity of infection (MOI) 1 and MOI5 C. pneumoniae infections of
THP-1 macrophages elevated the ROS production of the cells statistically significantly at 48 h post
infection. After 72 h infection ROS levels were elevated in MOI5-infected samples. When THP-1
macrophages were treated with schisandrin and schisandrin C, no differences in basal ROS levels
were observed after 4–48 h exposure. After 72 h schisandrin and schisandrin C elevated ROS levels at
both 25 µM and 50 µM concentration (Figure 4B). The concomitant administration of schisandrin and
schisandrin C with MOI5 C. pneumoniae infection did not change the detected ROS levels compared to
a vehicle-treated infection control (Figure 4C).
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The impact of C. pneumoniae infection and schisandrin lignans on redox status of THP-1
macrophages was further studied by determining cellular glutathione (GSH) concentrations after
infection, lignan treatment, or the combination of these two. As shown in Figure 5A, C. pneumoniae
infection caused a time—and infection MOI-dependent elevation in cellular GSH levels, detectable
48–72 h post infection.
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(A) THP-1 cells were infected with C. pneumoniae at MOI1 and MOI5 for 48 and 72 h. (B) THP-1 cells
were exposed to schisandrin lignans for 4 to 72 h. (C) Cells were infected with MOI5 and exposed to
schisandrin lignans for 48 and 72 h. Total GSH concentrations were determined and normalized to total
protein c ncentration of the sample. Data are shown as a r tio of 0.25% DMSO control an s as
mean ± SEM (n = 4). Statistical significance is presented as f p-values: < .05: *. Abbreviations:
Sch = schisandrin, MOI = f i fection.
Our previous studies in monocytic THP-1 cells showed that the lignans affect cellular glutathione
metabolism by causing a decrease in total GSH pools [25]. Similar to monocytic THP-1 cells, THP-1
macrophages exhibited remarkably lowered GSH pools after lignan treatment (Figure 5B), and a drastic
decrease in GSH levels was also observed in C. pneumoniae-infected THP-1 macrophages after lignan
exposure (Figure 5C).
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The relevance of GSH depletion in the lignans’ activities on C. pneumoniae infection phenotype
was evaluated by supplementing the infected cultures with GSH ethyl ester. While administration of
this cell-permeable GSH derivative alone increased EB yields by approximately 65%, supplementation
of schisandrin-treated infections yielded infectious progeny levels similar or lower than those in the
infection control (Figure 6). The GSH supplementation was thus sufficient to eliminate the elevating
effect of the 25 µM schisandrin treatment on bacterial progeny production.
Molecules 2020, 25, x FOR PEER REVIEW 8 of 17 
 
The relevance of GS  depletion in the lignans’ activities on C. pneu oniae infection phenotype 
as evaluated by supple enting the infected cultures ith GS  ethyl ester. hile ad inistration of 
this cell-permeable GSH derivative alone increased EB yields by approximately 65%, 
supplementation of schisandrin-treated infections yielded infectious progeny levels similar or lower 
than those in the infection control (Figure 6). The GSH supplementation was thus sufficient to 
eliminate the elevating effect of the 25 µM schisandrin treatment on bacterial progeny production. 
 
Figure 6. The impact of glutathione supplementation on schisandrin-induced changes in C. 
pneumoniae elementary body (EB) production. Data are normalized to the non-treated infection 
control and shown as a mean ± SEM (n = 4). Abbreviations: Sch = schisandrin. 
3. Discussion 
Current medication of chlamydial infections relies mostly on macrolide and tetracycline 
antibiotics and recurrent infections emerging after the antibiotic therapy are commonly observed. As 
obvious also from our data on the failure of azithromycin to clear the C. pneumoniae infection from 
monocyte-derived macrophages, improved antichlamydial agents active also on dormant bacteria 
are urgently needed. While azithromycin did clear the culture supernatants from infectious bacterial 
progeny, it was able to only partially suppress the intracellular bacteria loads. In this respect, the 
efficacy of schisandrin C was superior to azithromycin, as both intracellular and extracellular bacteria 
were cleared from the cultures by the lignan. Furthermore, the concomitant administration of 
schisandrin with azithromycin significantly improved the antichlamydial efficacy compared to sole 
azithromycin treatment. Based on these findings as well as the observation of increased EB progeny 
production by schisandrin, we propose that schisandrin acts as a C. pneumoniae phenotypic switcher. 
By shifting the intracellular bacteria populations to favor the replicative rather than dormant 
phenotype, it improves the antibiotic efficacy of azithromycin. 
To date, only a few drug-like molecules have been described as phenotypic switchers reverting 
persister bacteria from dormancy to active growth [4,26,27] and to our knowledge, the schisandrin 
lignans represent the first phenotypic switchers described to be active on intracellular bacteria. Based 
on rodent bioavailability studies, micromolar plasma concentrations of the lignans can be achieved 
after a single oral dose [28], indicating the potential of the lignans as scaffolds for orally administered 
drugs. Furthermore, our in vitro cell viability data (Table 2) and the numerous in vivo studies on 
these compounds [29] indicate the lack of acute or subacute toxicity of the lignans. It is, however, 
noteworthy that THP-1 macrophage viability was significantly decreased by high concentrations of 
schisandrin B (Table 1). In our earlier studies with epithelial cells and undifferentiated, monocytic 
THP-1 cells schisandrin B was well tolerated [16,25] highlighting the cell-type dependent bioactivities 
of these lignans. 
As key players in innate immunity, macrophages respond to microbes and other danger signals 
by generating effector molecules such as reactive oxygen species (ROS) and nitric oxide (NO) 
intended to kill the pathogen [30]. While NADPH oxidase is considered the major source of ROS in 
Figure 6. The impact of glutathione supplementation on schisandrin-induced changes in C. pneumoniae
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3. Discussion
Current medication of chlamydial infections relies mostly on macrolide and tetracycline antibiotics
and recurrent infections emerging after the antibiotic therapy are commonly observed. As obvious also
from our data on the failure of azithromycin to clear the C. pneumoniae infection from monocyte-derived
macrophages, improved antichlamydial agents active also on dormant bacteria are urgently needed.
While azithromycin did clear the culture supernatants from infectious bacterial progeny, it was able to
only partially suppress the intracellular bacteria loads. In this respect, the efficacy of schisandrin C
was superior to azithromycin, as both intracellular and extracellular bacteria were cleared from the
cultures by the lignan. Furthermore, the concomitant administration of schisandrin with azithromycin
significantly improved the antichlamydial efficacy compared to sole azithromycin treatment. Based
on these findings as well as the observation of increased EB progeny production by schisandrin, we
propose that schisandrin acts as a C. pneumoniae phenotypic switcher. By shifting the intracellular
bacteria populations to favor the replicative rather than dormant phenotype, it improves the antibiotic
efficacy of azithromycin.
To date, only a few drug-like molecules have been described as phenotypic switchers reverting
persister bacteria from dormancy to active growth [4,26,27] and to our knowledge, the schisandrin
lignans represent the first phenotypic switchers described to be active on intracellular bacteria. Based
on rodent bioavailability studies, micromolar plasma concentrations of the lignans can be achieved
after a single oral dose [28], indicating the potential of the lignans as scaffolds for orally administered
drugs. Furthermore, our in vitro cell viability data (Table 2) and the numerous in vivo studies on
these compounds [29] indicate the lack of acute or subacute toxicity of the lignans. It is, however,
noteworthy that THP-1 macrophage viability was significantly decreased by high concentrations of
schisandrin B (Table 1). In our earlier studies with epithelial cells and undifferentiated, monocytic
THP-1 cells schisandrin B was well tolerated [16,25] highlighting the cell-type dependent bioactivities
of these lignans.
As key players in innate immunity, macrophages respond to microbes and other danger signals
by generating effector molecules such as reactive oxygen species (ROS) and nitric oxide (NO) intended
Molecules 2020, 25, 294 9 of 16
to kill the pathogen [30]. While NADPH oxidase is considered the major source of ROS in stimulated
macrophages, mitochondrial ROS production also takes part in macrophage responses to bacterial
invaders via Toll-like receptor (TLR) signaling [31]. The significance of mitochondria in innate
immune responses is supported also by the findings indicating that mitochondria are targets of active
manipulation by intracellular pathogens such as Chlamydia spp. Rather than simply escaping innate
immunity responses, C. pneumoniae has been suggested to exploit them to drive virulence and successful
infections, illustrated by the NLRP3 inflammasome activation and its contribution to C. pneumoniae
survival in macrophages [32].
Earlier work on anti-persister agents has indicated that promotion of oxidative stress by
increased ROS production eradicates persister bacteria and enhances bacterial killing by conventional
antibiotics [33,34]. The medicinal plant-derived schisandrin lignans have been reported to harbor
a spectrum of biological activities, such as neuro- and cytoprotective as well as anti-inflammatory
properties [29]. The pharmacology of schisandrin lignans is linked to their ability to affect cellular
redox status and in particular, their modulation of mitochondrial functions [35,36]. Despite the impact
of the lignans on macrophage basal ROS levels (Figure 4B), ROS promotion is not likely the primary
mode of action of the compounds against C. pneumoniae, as the infection-induced ROS levels show no
difference between treated and non-treated cells (Figure 4C). Furthermore, similar impact on basal ROS
levels was observed for schisandrin and schisandrin C despite their opposite effects on C. pneumoniae
progeny yields (Table 2).
Consistent with earlier findings [37,38], we observed time-dependent fluctuation of GSH pools
after chlamydial infection, which can be considered a homeostatic response of the host to the
infection-induced increase in ROS levels. Our replication results show that despite the elevated ROS
levels (Figure 4A) and altering GSH levels (Figure 5A) during infection, a significant fraction of the
bacteria maintains an actively replicating phenotype. Thus, in contrast to murine macrophages [39,40]
the oxidative environment seems not to result in purely persistent infection phenotype in human-derived
THP-1 macrophages.
We also observed a remarkable decrease of THP-1 macrophage GSH levels upon lignan treatment.
While our earlier studies with monocytic THP-1 cells show glutathione pool suppression by the
lignans [25], earlier work has indicated that schisandrin C may increase GSH levels in the central
nervous system [41] and several related lignans may prevent oxidant-induced GSH depletion in
liver [17]. Based on these findings, it seems obvious that the effects of dibenzocyclooctadiene lignans
on mammalian cell glutathione metabolism are dependent on target cells or tissues as well as the
physiological conditions.
The lignan-induced decrease in GSH levels and the ability of GSH supplementation to revert
infectious progeny production elicited by schisandrin indicate that the lignans’ impact on C. pneumoniae
infection may involve modulation of GSH homeostasis. The cellular GSH balance may affect intracellular
bacteria by a variety of mechanisms. GSH has been found to act as a major cysteine source of
intracellular bacteria [42] and it has been reported to indirectly affect chlamydial energy supply by
increasing cell wall permeability [43]. GSH depletion is also known to induce K+ eﬄux [44] which,
in turn, can promote the chlamydial replication via the induction of NLRP3 inflammasome in the
host cells [32]. On the other hand, GSH and its metabolites are directly toxic to some intracellular
bacteria [45] and the GSH-dependent changes in cellular redox status may detrimentally affect
C. pneumoniae survival, as suggested in murine models [37]. Interestingly, GSH is also known to
induce virulence gene expression of Listeria monocytogenes [46], implying that it may serve as an
indicator of the local environment, directing virulence gene expression of intracellular bacteria. To date,
processes linked to the ability of Chlamydia spp. bacteria to sense their microenvironment have
remained poorly understood, and the potential role of GSH in chlamydial adaptation and balance
between active and persistent phenotype warrants further investigation. By unraveling this aspect of
chlamydial biology, the schisandrin lignans act as chemical probes providing valuable insights into
pathogen–host interactions.
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Despite their similar effects on cellular ROS and GSH levels, schisandrin and schisandrin C
show differential activity on the C. pneumoniae infection in THP-1 macrophages. This may reflect two
separate aspects of their biological activities: a redox-dependent phenotypic switch by C. pneumoniae
from persister to active replication and a polypharmacological nature of antichlamydial action by
schisandrin C.
Our earlier findings applying permissive epithelial cells demonstrate that schisandrin C exhibits
chlamydiocidal activity in the acute infection model [16]. In contrast, schisandrin does not affect
C. pneumoniae replication at 25 µM concentration. Based on these observations, we propose that
depleting cellular GSH by both of the studied lignans stimulates chlamydial growth, and persistent
infection is converted to active state. In the case of schisandrin this is seen as the promotion of infectious
progeny formation. Schisandrin C, on the other hand, seems to act via two distinct mechanisms:
switching bacteria from persistence to active growth and active killing of the replicative bacteria.
4. Materials and Methods
4.1. General
The purity of the lignans was determined by HPLC and were 99.0% for schisandrin, 98.0%,
for schisandrin B, and 98.6% for schisandrin C. The nuclear magnetic resonance (NMR) spectra
(1H NMR, 13C NMR) (available as Supplementary Material) of the key target compounds schisandrin
and schisandrin C were recorded on a Bruker Ascend 400—Avance III HD NMR spectrometer (Bruker
Corporation, Billerica, MA, USA). Chemical shifts (δ) are reported in parts per million (ppm) relative
to the NMR solvent signals (DMSO-d6 2.50 ppm and 39.50 ppm for 1H and 13C NMR, respectively).
4.2. Compounds
Schisandrin was obtained from Sigma-Aldrich, St. Louis, MO, USA and schisandrin B and
schisandrin C were purchased from Fine Tech Industries, London, UK. 1H and 13C NMR of schisandrin
and schisandrin C showed corresponding peaks and multiplicities as reported in the literature [47].
Deviations in the chemical shifts (due to different NMR solvents and spectrometers) were not greater
than 0.28 ppm (1H) and 1.64 ppm (13C) for schisandrin, and 0.11 ppm (1H) and 0.88 ppm (13C) for
schisandrin C.
Schisandrin: White solid; 1H NMR (400 MHz, DMSO-d6) δ = 6.73 (s, 1H), 6.66 (s, 1H), 3.98 (s,
1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.72 (s, 3H), 3.72 (s, 3H), 3.40 (s, 3H), 3.39 (s, 3H), 2.71 (dd, J = 13.8, 2.0 Hz,
1H), 2.37 (d, J = 13.3 Hz, 1H), 2.29 (t, J = 4.2 Hz, 1H), 2.25 (t, J = 4.1 Hz, 1H), 1.71–1.64 (m, 1H), 1.12 (s,
3H), 0.70 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ = 151.2, 151.2, 151.0, 150.6, 139.4, 139.3,
134.5, 133.7, 122.8, 122.8, 111.2, 110.6, 70.9, 60.4, 60.3, 60.0 (2C), 55.7, 55.5, 41.1, 40.5, 34.2, 30.0, 15.6.
Schisandrin C: White solid; 1H NMR (400 MHz, DMSO-d6) δ = 6.57 (s, 2H), 5.99 (s, 2H), 5.99–5.98
(m, 2H), 3.72 (s, 3H), 3.70 (s, 3H), 2.54–2.48 (m, 1H*), 2.26–2.23 (m, 1H), 2.08–2.03 (m, 1H), 1.98–1.95 (m,
1H), 1.84–1.76 (m, 1H), 1.70–1.60 (m, 1H), 0.92 (d, J = 7.1 Hz, 3H), 0.65 (d, J = 7.1 Hz, 3H). 13C NMR
(101 MHz, DMSO-d6) δ = 148.3, 147.2, 140.7, 140.5, 137.5, 134.2, 133.9, 132.1, 121.7, 120.6, 105.6, 102.7,
100.7, 100.7, 59.0, 59.0, 40.4, 38.0, 34.5, 32.9, 21.3, 12.2. *Overlap with solvent, verified by HSQC.
The lignans, as well as azithromycin (≥98%, Cayman Chemicals, Ann Arbor, MI, USA) used as a
reference antibiotic were dissolved in dimethyl sulfoxide (DMSO) and diluted in cell culture media at
indicated concentrations.
4.3. Cell Culture
All cell cultures were maintained at 37 ◦C, 5% CO2, and 95% air humidity. THP-1 cells
(ATCC TIB-202, RRID: CVCL_0006) were maintained in RPMI 1640 Dutch edition medium (Gibco,
Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (BioWhittaker,
Lonza, Basel, Switzerland), 2 mM l-glutamine (BioWhittaker, Lonza, Basel, Switzerland), 0.05 mM
mercaptoethanol (Gibco, Invitrogen, Thermo Fisher) and 20 µg/mL gentamicin (Sigma-Aldrich,
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St. Louis, MO, USA). For differentiation into macrophage-like cells, THP-1 cells were incubated for
48–72 h with 160 nM phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA).
Human HL cells [48] were obtained from professor Pekka Saikku/National Health Institute and
University of Oulu, Finland) and maintained in RPMI 1640 (BioWhittaker, Lonza, Basel, Switzerland)
supplemented with 7.5% FBS, 2 mM l-glutamine and 20 µg/mL gentamicin. When seeding HL cells
into well plates, an overnight incubation was applied prior to the experiment.
4.4. Infections
For qPCR and infectious progeny experiments, the cells were seeded into 24-well plates (HL cells
at a density of 4 × 105 cell per well, THP-1 macrophages 3.5 × 105 cell per well) and infected with
C. pneumoniae (strain CV-6, obtained from professor Matthias Maass, Paracelsus Medical University,
Salzburg, Austria, propagated as previously described [49]). Cell monolayers were centrifuged at
550 g for 1 h and incubated 1 h in 37 ◦C. Then, fresh medium or medium with compounds was added
and the cultures were incubated from 24 to 144 h. To determine effect of GSH on C. pneumoniae
infection, 2 mM GSH ethyl ester was added to the infected cultures at 2, 24, or 48 h post infection.
For HL cell infections, cell culture medium was supplemented with 1 µg/mL of cycloheximide (CHX,
Sigma-Aldrich, St. Louis, MO, USA).
4.5. Quantitative PCR
DNA from cell cultures was extracted with a GeneJet Genomic DNA purification kit (Thermo
Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions for mammalian cells.
The DNA concentration in samples was measured with Multiskan Sky Microplate spectrophotometer
by µDrop Plate and the DNA was stored at −20 ◦C until use. An established qPCR method on
C. pneumoniae ompA gene [50] was applied to quantify C. pneumoniae genome copy numbers. Using
Step One plus Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The primers
were selected for qPCR run as follows: forward primer, VD4F (5′-TCC GCA TTG CTC AGC C-3′)
and reverse primer, VD4R (5′-AAA CAA TTT GCA TGA AGT CTG AGA A-3′). The reactions were
prepared in 96-well MicroAmp optical plate by adding 20 ng of extracted DNA to 10 µL of master mix
to 20 µL qPRC reaction. Detection was performed with Step One plus Real-Time PCR system by using
the manufacturer’s standard protocol. Conditions in thermal cycle were 95 ◦C for 20 s and 40 cycles
of 95 ◦C for 3 s and 60 ◦C for 30 s. All qPCR experiments were run with four biological replicates,
each quantified as two technical replicates.
4.6. Infectious Progeny Assay
The EBs were harvested from infected THP-1 macrophages at various time points (72–144 h) post
infection by collecting the culture supernatants, centrifuging them at 21,000 rpm for 1 h in 4 ◦C and
resuspending the pellets with 0.2 mL of fresh cold medium. Monolayer cells from the same samples
were scraped to 0.2 mL of fresh cold medium. All samples were stored in −80 ◦C.
The bacterial progeny in the samples was quantified by inoculating them on HL monolayers
with CHX. After infection, fresh medium with CHX was added and cells were incubated for 70 h. Then,
cells were fixed and stained with a genus-specific anti-LPS antibody (Pathfinder, Bio-rad, Hercules, CA,
USA). Chlamydial titers were determined based on the inclusion counts observed with fluorescence
microscope. The experiments were performed with four biological replicates, each quantified as a
minimum of six technical replicates.
4.7. Resazurin Assay
THP-1 cells were seeded into 96-well plates at density of 6 × 104 cells/well and the cells were
differentiated with 160 nM of PMA. After differentiation, 10, 25, and 50 µM of schisandrin, schisandrin B,
and schisandrin C was added to the wells. Usnic acid (50 µM, Sigma-Aldrich, St. Louis, MO, USA)
was used as positive control and 0.25% DMSO as a vehicle control. Cells were incubated for 24–144 h.
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Culture medium with samples was replaced with fresh aliquots at 72 h in the 144 h experiment. After
incubation, resazurin (Sigma-Aldrich, St. Louis, MO, USA) in PBS was added in a final concentration
of 20 µM. The culture was incubated for further 2 h and fluorescence was recorded at 570/590 nm with
Varioskan Lux plate reader. The experiments were performed with three biological replicates.
4.8. ATP Quantification Assay
THP-1 cells were seeded into 96 well plates at density of 2× 104 cells/well. Cells were differentiated
with 160 nM PMA for 72 h. Then cells were infected with MOI1 of C. pneumoniae and after 1 h
centrifugation at 550 g and 1 h incubation at 37 ◦C cells were exposed to 10, 25, and 50 µM of
schisandrin, schisandrin B and schisandrin C. After 24, 48, and 72 h incubation, 100 µL of CellTiter-Glo
reagent (Promega, Madison, WI, USA) was added to the wells and the plate was incubated for 10 min
at room temperature. To minimize the leakage of the signal, 100 µL of the lysate was transferred to a
white 96-well plate. Luminescence was recorded with Varioskan Lux plate reader. The experiments
were performed with three biological replicates.
4.9. Intracellular ROS Detection Assay
THP-1 macrophages in 96-well plate (6 × 104 cells/well) were subjected to an infection by
C. pneumoniae, treatment with the schisandrin lignans or a combination of these two, using a culture
medium without mercaptoethanol. In experiments with 1–4 h exposure, the cells were preloaded
with 20 µM DCFH-DA (Sigma-Aldrich, St. Louis, MO, USA) for 30 min and washed with PBS prior
to lignan administration. After 24–72 h exposures, cells were washed once with PBS, loaded with
DCFH-DA for 30 min, washed with PBS and incubated for further 3 h. After that, fluorescence was
recorded at 503/523 nm with Varioskan Lux plate reader. The experiment was performed as four
biological replicates.
4.10. Glutathione Quantification Assay
The intracellular GSH levels of THP-1 macrophages after C. pneumoniae infection, lignan treatment
or combination of these two were determined using enzymatic recycling method described previously by
Rahman et al. [51]. In brief, THP-1 monocytes were seeded into 6-well plate at density of 5 × 105 cells/mL
in cell culture medium without mercaptoethanol and differentiated into macrophages with PMA.
The monolayers were exposed to either the lignan treatment (25 µM and 50 µM), C. pneumoniae infection
(MOI5) or the combination of these two and incubated for a time indicated for each experiment.
0.25% DMSO were used as vehicle control. Cells were then collected, lysed and stored at −70 ◦C.
To quantify GSH, glutathione reductase (GR) and 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) were
added to the sample. After 30 s, β-NADPH were added and the formation of TNB chromophore,
which is proportional to GSH concentration in the sample, was detected by multiskan Sky plate reader
(Sigma-Aldrich). The concentrations of GSH were applied using linear regression to calculate the
values obtained from the standard curves.
For data normalization, total protein concentration determination of the cell lysates was performed
with acetone precipitation. 100 µl of cell lysate sample was heated 5 min at 95 ◦C and 400 µl of cold
(−20 ◦C) acetone was added. Sample was mixed and incubated 1 h at −20 ◦C, centrifuged at 15,000 g
and supernatant was discarded. Pellet was resuspended to 100 mM Tris-buffer (pH; 7.5) and protein
concentration was detected with Multiskan sky, µDrop plate. Sample purity was evaluated with
260/280 ratio values. The presented data are derived from two biological replicates both performed as
two technical replicates (n = 4).
4.11. Data Analysis
Statistical tests were performed using SPSS Statistics 24 software. Differences between means
were calculated with Student’s t-test with Bonferroni correction. P-values < 0.05 were considered
statistically significant. Outliers were defined from data by Grubbs test, in significance level 0.05.
Molecules 2020, 25, 294 13 of 16
5. Conclusions
The current work demonstrates that the dibenzocyclooctadiene lignans schisandrin and schisandrin
C possess antichlamydial activities that are qualitatively and quantitatively distinct from each other and
the reference antibiotic azithromycin. The presented data also indicates that these activities are linked
to the suppression of macrophage glutathione pools by the lignans. Redox status and glutathione
homeostasis have recently emerged as modulators for intracellular bacteria virulence [46,52], indicating
that targeting cellular redox mechanisms may offer a means for inducing a phenotypic switch in
pathogenic bacteria. The superiority of schisandrin C compared to azithromycin in its ability to eliminate
both active and persistent bacteria in THP-1 macrophages highlights the potential of this strategy in
anti-persister therapy, triggering future research on nonconventional antibacterials. Furthermore, ability
of schisandrin to resuscitate C. pneumoniae infection to the standard-of-care antibiotic azithromycin
shows potential for further translational studies on these medicinal plant-derived compounds.
Supplementary Materials: The following are available online. NMR spectra for schisandrin and schisandrin C.
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